Keywords: long-term, atac, data, supports, arimidex, over, tamoxifen

Long-term ATAC data supports Arimidex over tamoxifen

Article | 22 December 2006

Print This

Anglo-Swedish drug major AstraZeneca says that new data presented at the 29th annual San Antonio Breast Cancer Symposium confirm that, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in